The accuracy of prostate-specific antigen (PSA) screening can be improved by including genetic factors that cause changes in PSA levels not associated with cancer, according to a multi-center study.
Experts argue that shared decision policies between patients and their doctors have led to high rates of PSA testing and clear medical harm, with minimal benefit and inequity.
Like the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer.
A new clinical trial has shown that men diagnosed with prostate cancer can benefit from ‘radical radiotherapy’ that delivers treatment in five hospital visits instead of the typical 20.
An advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a clearer view of suspected tumours during biopsy.
Researchers demonstrate a HoloLens AR system that enables accurate, flexible needle guidance for transperineal prostate interventions such as biopsy, focal laser ablation, and brachytherapy
Researchers have developed a new blood test to detect prostate cancer which displays greater accuracy than the current prostate-specific antigen (PSA) method.
In men recently diagnosed with intermediate or high-grade prostate cancer, PSMA PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.
An advanced radiotherapy technique can be used to safely treat prostate cancer patients in as little as one to two weeks, compared with the current standard, which takes one to two months.
A new randomized study confirms that men with high-risk prostate cancer can be treated with a moderately shortened course (5 vs. 8 weeks) of radiation therapy.
Focal treatment of prostate cancer involves treating only the tumor and not the entire gland, sparing surrounding tissue and nerves. The method is being evaluated in a research study.
Machine learning and artificial intelligence (AI) have the potential to transform cancer treatment management worldwide. Their ability to rapidly analyse and integrate routinely acquired diverse data will improve the accuracy and effectiveness of precision medical treatments.
Researchers in Sweden have now discovered a faster and easier way to determine who has an aggressive form of prostate cancer, and who has not.
A different way of treating people with prostate cancer will be investigated by researchers at the University of Leeds in a new clinical trial funded by Yorkshire Cancer Research.
Synthetic correlated diffusion makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.
UK researchers have found that a new type of ultrasound scan can diagnose most prostate cancer cases with good accuracy in a clinical trial involving 370 men.
Mathematical models used as patient surrogates could help clinicians select the best cancer treatment before going to the patient’s bedside.
A new risk calculator could reduce the number of unnecessary and invasive biopsies for prostate cancer.
The combination of a novel blood test and magnetic resonance imaging can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a new study.
Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast and ovarian cancer. Now, they have been linked to several other cancers, including those that affect men.
A team led by the University of Washington has developed a new, non-destructive method that images entire 3D biopsies instead of a slice. The 3D images provided more information than a 2D image — specifically, details about the tree-like structure of the glands throughout the tissue.
Researchers have found that regular blood tests can help detect whether prostate cancer patients have resistance to drugs treating the condition. The findings were presented at the National Cancer Research Institute (NCRI) virtual Festival.
Organised screening enabling early detection and treatment of prostate cancer can reduce death by an impressive 20%, based on 16 years of findings of over 160,000 men participating in the landmark European Randomised Study of Screening for Prostate Cancer (ERSPC).
For nuclear medicine specialists, 2021 may be heralded as a banner year validating the use of theranostic technology to treat cancer. Long-awaited results from the international phase 3 clinical VISION trial spark confidence in many experts.
Research led by the Queensland University of Technology (QUT) on the interaction between prostate cancer cells and the tumour microenvironment has shed more light on the propensity of some types of prostate cancer to metastasize to bone more readily than other types.